Search results
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And...
Benzinga via Yahoo Finance· 11 hours agoThe terms of the agreement include: A co-exclusive license to co-commercialize Novavax’s current...
Novavax stock doubles after Sanofi deal marks 'new chapter' for company
Yahoo Finance· 5 hours agoNovavax stock (NVAX) skyrocketed on Friday, nearly doubling on the news French drug and vaccine...
Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine...
WKBN 27 Youngstown· 19 hours ago...worldwide (except in countries with existing Advance Purchase Agreements and in India, Japan and South Korea where Novavax has existing partnership agreements); a sole license to Novavax's adjuvanted COVID-19 vaccine for use in combination with Sanofi's flu vaccines while Novavax retains the...
Novavax gets a lifeline with Sanofi vaccine pact
BioPharma Dive via Yahoo Finance· 16 hours agoSanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination...
Novavax Reports First Quarter 2024 Financial Results and Operational Highlights
CBS 47 Fresno· 19 hours ago...combination product near-term milestones, plus ongoing tiered royalties on product salesUp to $200 million in milestones plus royalties for each new vaccine developed utilizing Novavax's Matrix-MTM adjuvantAnnounces addition of standalone influenza vaccine to Phase 3 COVID-19-Influenza...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with Strategic Partnerships and Cost ...
GuruFocus.com via Yahoo Finance· 8 hours agoFurthermore, the company is preparing for the upcoming vaccination seasons by advancing its COVID-19 vaccine and initiating Phase 3 trials ...
Novavax Inc (NVAX) Q1 2024 Earnings: Navigating Challenges with
Guru Focus· 8 hours agoThe company, a prominent player in the biotechnology sector focusing on the development of vaccines, reported a net loss of $147.55 million with a loss per share of $1.05.
AstraZeneca’s COVID vaccine withdrawn – right to the end it was the victim of misinformation -...
EconoTimes· 2 days agoThe Oxford-AstraZeneca vaccine was a critical part of the COVID-19 pandemic response. This EU...
Morning Brew: Novavax Soars on Sanofi Deal, Roblox Rebounds on U
Guru Focus· 11 hours agoStock market futures indicate a positive opening for the final trading day of the week. Here's a...
An adjuvant made in yeast could lower vaccine cost and boost availability
UC Berkeley NewsCenter· 3 days agoVaccines save lives, as proven during the recent pandemic, but one component of most vaccines —...